August 17
To download program at a glance of UAA Congress 2025 :
17th August 2025
| Time | Session | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
08:30
12:00
|
||||||||||
|
08:30
10:00
|
||||||||||
|
08:30
15:30
|
||||||||||
|
10:00
10:30
|
||||||||||
|
10:30
12:00
|
||||||||||
|
10:30
12:00
|
BPH & Novel Advances (B)
Po-Ming ChowTaiwan
Moderator
Conventional Artificial Urinary Sphincter ImplantationA step-by-step video of a standard approach of AUS implatation is shown in this semi-live session.
TICC - 1F 101C
|
Oncology Prostate (F)
TICC - 1F 101D
|
Oncology Bladder (B)
TICC - 3F South Lounge
|
|||||||
|
12:00
13:00
|
Global Impact and Transforming HIV Prevention of Shang Ring Male Circumcision
TICC - 3F Banquet Hall
|
A New Era in Precision Diagnosis and Localized Therapy in PCa with Micro-Ultrasound (ExactVu) and Focal One Robotic HIFU
TICC - 2F 201BC
|
The Role of Immunotherapy in adj./mRCC, Updated Evidence and Clinical Practice
TICC - 2F 201DE
|
Breaking New Ground: PARPi + ARPi Combination Therapy in mCRPC
TICC - 2F 201AF
|
Offers an Optimized Solution for MIUC Patients with Nivolumab
TICC - 1F 101A
|
|||||
|
12:00
13:00
|
Optimizing Treatment and The Role of PARPi and ARPi in PC
TICC - 1F 101B
|
Maximizing Treatment Outcomes in Advanced Prostate Cancer: Strategies for Optimal Patient Care
TICC - 1F 101C
|
The Japanese Surveillance and JAID/JSC Guidelines 2023: The Usefulness of the Urinary Flow Cytometry Method (uFCM)
TICC - 1F 101D
|
Shaping a New Era: IO Perioperative Therapy in MIBC
TICC - 3F South Lounge
|
||||||
|
13:30
15:30
|
Yen-Chuan OuTaiwan
Moderator
ARUS–PRUS Partnership Ceremony: A New Chapter in Asia Robotic Urology CollaborationDear colleagues and friends,
It’s a great honor to witness the signing of this partnership between the Asian Robotic Urology Society (ARUS) and the Philippines Robotic Urology Society (PRUS).
This marks the beginning of a new chapter in regional collaboration—one that emphasizes shared training, joint research, and mutual support to advance robotic urology across Asia. PRUS brings energy, expertise, and vision to this partnership, and ARUS is proud to walk alongside you as we work toward higher standards and better outcomes for our patients. Let us move forward together—with unity, purpose, and innovation.
Congratulations to both ARUS and PRUS!Aquablation Revolutionizing BPH Treatment: A New Era of Minimally Invasive Therapy-Tungs' Taichung Metroharbor Hospital ExperienceIntroduction
Aquablation is a waterjet ablation therapy for benign prostatic hyperplasia (BPH) that has gained significant attention. While its efficacy, durability, and safety have been established across various prostate sizes (30–150 mL), local data on its efficacy, safety, and learning curve in Taiwan remain limited. Our team have been performed 85 cases between March 2024 and July 2025. This lecture presents the learning curve observed in the first 50 patients who underwent Aquablation for BPH, highlighting its role in revolutionizing BPH treatment.
Materials and Methods
We conducted a retrospective review of 50 consecutive patients who underwent Aquablation between March 2024 and February 2025, dividing them into two groups: Group I (first 25 cases) and Group II (subsequent 25 cases). Assessments included IPSS, QoL, uroflowmetry parameters (voiding volume, Qmax, Qmean, PVR), operative time, hemoglobin drop, Clavien-Dindo grade ≥2 complications, hospital stay, and urethral catheter duration.
Results
Patients in Group II were younger and had smaller prostates. Aquablation was successfully performed in all cases. IPSS, QoL, voiding volume, Qmax, and Qmean improved significantly and were sustained for three months, while PVR improved only in Group I. Operative time was significantly shorter in Group II, and hemoglobin drop was greater in Group I. Complication rates, hospital stay, and catheter duration were similar between groups.
Conclusions
Aquablation provided significant and immediate improvements in voiding parameters and symptoms, with sustained PVR benefits in larger prostates. Surgeon proficiency improved after 25 cases. Overall, Aquablation proved safe and effective, even in an unselected patient population. Aquablation represents a promising advancement that could transform the therapeutic landscape for BPH—particularly if costs are reduced.Experience of 100 Consecutive Hugo Robotic Radical ProstatectomiesIntroduction and background:
Dr. Ou’ surgical team of Tungs’ Taichung MetroHarbor Hospital performed the first Hugo robotic radical prostatectomy on May 9, 2023. In 2023, we published the results of the first series of 12 Hugo robotic radical prostatectomies performed. In 2024, we published a comparison of 30 Hugo robotic radical prostatectomies and 30 Da Vinci robotic radical prostatectomies. Professor Ou is the Hugo robotic arm instructor recognized by Medtronic. Many Southeast Asian doctors come to this Hospital to observe the surgery and learn.
Material and Methods:
We prospectively collected data for retrospective analysis and statistics from May 9, 2023 to April 30, 2025, performing 100 consecutive Hugo robotic radical prostatectomies. We compared the surgical results of 1-50 cases (group 1) and 51-100 cases (group 2). The data analyzed included basic information, age, risk of anesthesia, BMI , prostate-specific antigen, clinical stage, and Gleason score grade. The two groups were compared in terms of surgical difficulty, receipt of neoadjuvant hormonal therapy, obesity, prostate volume >70 g, prostate protrusion more than 1 cm into the bladder neck, previous transurethral resection of prostate, history of abdominal surgery, extensive pelvic lymphadenectomy, salvage radical prostatectomy, and time from biopsy to radical prostatectomy less than 6 weeks. The two groups were compared in terms of robotic console time, blood loss, blood transfusion rate, and surgical complications. We compared the two groups in terms of postoperative pathological staging and grade, the proportion of tumor, and the proportion of urinary control at one month and three months.
Results:
The study showed that the age of patients in the second group was slightly higher, but the statistical p value was 0.058, which did not reach statistical difference. The second group of patients had significantly higher rates of stage III, stage IV, lymph node and bone oligometastasis, with a p value of 0.021. The rate of neoadjuvant hormonal therapy received by the second group was 16 percent, which was statistically significant compared with 2 percent of the first group (p = 0.021). The rates of other surgical difficulty factors were the same between the two groups. The average blood loss of patients in the second group was 156 CC, which was significantly less than the 208 CC in the first group. The operation time and surgical complications were comparable between the two groups. The cancer volume of the second group of patients was significantly reduced compared with that of the first group (3.30±2.93 versus 5.09±5.24, p value=0.049). The reason was that more patients in the second group received neoadjuvant hormonal therapy, which significantly reduced the cancer. Both groups of patients had very good urinary control after surgery.
Conclusion:
We conclude that Hugo robotic radical prostatectomy is an effective and feasible method with extremely low complications and good recovery of urinary control function after surgery. After the experience of the first 50 operations, the surgeon will choose patients with higher difficulty, especially those receiving neoadjuvant hormone therapy, to perform the operation.Total Solution of Maintenance of Urinary and Sex Function during Robotic Radical ProstatectomyBackground:
Robotic-assisted radical prostatectomy (RARP) has become a preferred surgical approach for localized prostate cancer due to its minimally invasive nature and precision. However, the preservation of urinary continence and sexual function remains a significant postoperative challenge. Traditional outcomes have focused heavily on oncological safety. Yet, contemporary perspectives emphasize a more holistic view—embodied in the concept of the “Pentafecta,” which includes continence, potency, negative surgical margins, biochemical recurrence-free survival, and absence of perioperative complications.
Objective:
This presentation introduces a comprehensive and integrative approach aimed at maximizing functional outcomes—particularly urinary continence and erectile function—through a modified pubovesical complex-sparing RARP under regional hypothermia, supplemented with real-time nerve imaging, neurovascular preservation strategies, and biological enhancement techniques.
Methods:
We present data and experience from Tungs’ Taichung MetroHarbor Hospital (TTMHH), including a series of 3780 robotic procedures performed between December 2005 and July 2025. Among these, 100 cases were completed using the Hugo™ RAS system and 21 with the da Vinci SP™ platform. Our modified technique builds upon Dr. Richard Gaston’s pubovesical complex-sparing method, with the addition of localized hypothermia (24°C), near-infrared fluorescence (NIRF) imaging with indocyanine green (ICG), and application of dehydrated human amnion/chorion membrane (dHACM). In selected cases, nerve grafting with Axogen® technology was applied.
Results:
Initial results indicate a significantly improved early return of continence (95% by 16 weeks) and promising erectile function recovery, particularly in patients who received adjunctive therapies such as phosphodiesterase inhibitors or vacuum erection devices. The precision afforded by robotic technology enabled preservation of
prostate capsular arteries and accessory pudendal arteries. Localized hypothermia contributed to reduced tissue edema, minimized neural trauma, and improved nerve recovery. The use of ICG-NIRF allowed real-time identification of critical vascular landmarks, enhancing nerve-sparing accuracy. Preliminary analysis suggests our technique is both feasible and reproducible.
Conclusion:
The modified pubovesical complex-sparing RARP under hypothermia, augmented with vascular imaging and biologic materials, offers a promising paradigm for functional preservation in prostate cancer surgery. This total solution approach not only protects neurovascular integrity but also accelerates recovery of continence and potency.
Continued accumulation of clinical cases and controlled comparative studies are warranted to further validate the efficacy and long-term benefits of these techniques.
Significance:
This strategy reflects a patient-centered evolution in robotic prostate surgery, merging surgical innovation with anatomical preservation and technological augmentation. It represents an epic collaboration of surgical precision, team-based care, and thoughtful application of biomedical advances to improve quality of life outcomes in prostate
cancer patients.Total Solution of Maintenance of Urinary and Sex Function during Robotic Radical Prostatectomy
TICC - 3F Banquet Hall
|
Novel Advances (C)
Hsiang-Ying LeeTaiwan
Moderator
Best Laser for UTUCManagement of Total Ureteral Avulsion during Ureteroscopy
Osamu UkimuraJapan
Moderator
A Fully Automated Artificial Intelligence System to Assist Pathologists' Diagnosis to Predict Histologically High-Grade Urothelial Carcinoma from Digitized Urine CytologyBackground: Urine cytology, although a useful screening method for urothelial carcinoma, lacks sensitivity. As an emerging technology, artificial intelligence (AI) improved image analysis accuracy significantly.
Objective: To develop a fully automated AI system to assist pathologists in the histological prediction of high-grade urothelial carcinoma (HGUC) from digitized urine cytology slides.
Design, setting, and participants: We digitized 535 consecutive urine cytology slides for AI use. Among these slides, 181 were used for AI development, 39 were used as AI test data to identify HGUC by cell-level classification, and 315 were used as AI test data for slide-level classification.
Outcome measurements and statistical analysis: Out of the 315 slides, 171 were collected immediately prior to bladder biopsy or transurethral resection of bladder tumor, and then outcomes were compared with the histological presence of HGUC in the surgical specimen. The primary aim was to compare AI prediction of the histological presence of HGUC with the pathologist's histological diagnosis of HGUC. Secondary aims were to compare the time required for AI evaluation and concordance between the AI's classification and pathologist's cytology diagnosis.
Results and limitations: The AI capability for predicting the histological presence of HGUC was 0.78 for the area under the curve. Comparing the AI predictive performance with pathologists' diagnosis, the AI sensitivity of 63% for histological HGUC prediction was superior to a pathologists' cytology sensitivity of 46% (p = 0.0037). On the contrary, there was no significant difference between the AI specificity of 83% and pathologists' specificity of 89% (p = 0.13), and AI accuracy of 74% and pathologists' accuracy of 68% (p = 0.08). The time required for AI evaluation was 139 s. With respect to the concordance between the AI prediction and pathologist's cytology diagnosis, the accuracy was 86%. Agreements with positive and negative findings were 92% and 84%, respectively.
Conclusions: We developed a fully automated AI system to assist pathologists' histological diagnosis of HGUC using digitized slides. This AI system showed significantly higher sensitivity than a board-certified cytopathologist and may assist pathologists in making urine cytology diagnoses, reducing their workload.
Patient summary: In this study, we present a deep learning-based artificial intelligence (AI) system that classifies urine cytology slides according to the Paris system. An automated AI system was developed and validated with 535 consecutive urine cytology slides. The AI predicted histological high-grade urothelial carcinoma from digitized urine cytology slides with superior sensitivity than pathologists, while maintaining comparable specificity and accuracy.
Keywords: Artificial intelligence; Deep learning; The Paris System; Urine cytology; Urothelial carcinoma.
TICC - 2F 201DE
|
Functional Urology (D)
TICC - 2F 201AF
|
Oncology Prostate (F)
TICC - 1F 101A
|
||||||
|
13:30
15:00
|
Oncology Miscellaneous & Endourology (C)
TICC - 1F 101B
|
Novel Advances (D) & Andrology & Transplantation
TICC - 1F 101C
|
Andrology (D)
Chuan-Shu ChenTaiwan
Moderator
Severity of sexual dysfunction in Taiwanese patients with and without type 2 diabetes mellitus.introduction
Patients with type 2 diabetes are at a higher risk of developing sexual dysfunction. This study aims to investigate the current prevalence of sexual dysfunction in Taiwanese patients with and without type 2 diabetes mellitus(DM) and to explore patterns in how affected individuals seek management or treatment for this condition.
Materials and Methods
Between June 2023 and October 2024, a total of 450 patients visiting our urology outpatient department were invited to complete a questionnaire comprising the Men's Sexual Health Questionnaire (MSHQ) and supplementary questions assessing patterns of seeking management for sexual dysfunction.
Results
Of the 402 subjects who completed the questionnaire, 28.1% (113/402) had type 2 diabetes mellitus (DM). Among patients with varying degrees of sexual dysfunction, those in the DM group reported significantly greater severity across all domains of the MSHQ—erection, ejaculation, satisfaction, frequency of sexual activity, and sexual desire—compared to the non-DM group.
After applying propensity score matching for age and comorbid chronic diseases, the scores in each domain were as follows (DM group vs. non-DM group): erection (9.55 vs. 10.94, p = 0.028), ejaculation (25.87 vs. 28.26, p = 0.012), sexual desire (12.38 vs. 13.34, p = 0.020), satisfaction (20.51 vs. 21.64, p = 0.112), and frequency of sexual activity (10.29 vs. 10.58, p = 0.465).
Notably, 73% of patients with DM expressed a desire to discuss sexual health issues with their physicians. However, only 10% reported that their doctors had initiated such conversations. The most commonly cited reason for not discussing sexual problems was feeling embarrassed. Additionally, 54% of DM patients with sexual dysfunction reported receiving no form of management, despite 57% expressing interest in treatment.
Conclusions
The prevalence of sexual dysfunction and related concerns was high among diabetic patients; however, only a small proportion had sought professional help. Routine screening for sexual dysfunction in patients with diabetes is therefore recommended.
Hyun Jun Park Korea (Republic of)
Moderator
The Evolutionary Role of Varicocelectomy in Andrology Varicocelectomy is among the most commonly performed surgical procedures in contemporary andrological practice. Historically, varicocele management focused primarily on alleviating symptomatic discomfort and addressing infertility characterized by impaired semen parameters. However, the conceptual framework and indications for varicocelectomy have evolved significantly over recent decades, reshaping its clinical implications and expanding its therapeutic potential.
Initially, open surgical approaches such as retroperitoneal and inguinal varicocelectomy were predominant, yet they carried considerable risks, including recurrence, hydrocele formation, and potential damage to testicular arteries. With the advent of microsurgical techniques, particularly subinguinal microsurgical varicocelectomy, procedural efficacy and safety have markedly improved. This has resulted in reduced complication rates and enhanced fertility outcomes, positioning microsurgical varicocelectomy as the current gold standard.
Modern andrological literature emphasizes varicocelectomy’s broader physiological benefits beyond fertility. Recent studies highlight its role in improving testosterone production, mitigating hypogonadism, and enhancing overall testicular function. Additionally, varicocelectomy has been demonstrated to significantly improve sperm DNA integrity and reduce oxidative stress levels, thus positively impacting assisted reproductive technology (ART) outcomes.
Furthermore, contemporary research suggests that varicocelectomy may provide systemic health benefits by reducing chronic inflammation and oxidative damage, conditions associated with metabolic and cardiovascular disorders. This evolving understanding positions varicocelectomy not merely as a fertility treatment but as an integral part of comprehensive male reproductive health management. These insights prompt a proactive approach, encouraging clinicians to recognize varicocelectomy’s extended potential in enhancing male reproductive longevity and general health.
In conclusion, the evolution of varicocelectomy, characterized by advancements in surgical techniques and expanded clinical indications, underscores its significant role in modern andrology. An integrated appreciation of its multifaceted therapeutic benefits facilitates informed clinical decision-making, ultimately enhancing patient care and outcomes in andrological practice.
Yu-Sheng ChengTaiwan
Moderator
DNA Fragmentation’s Impact on Male Infertility: Advanced molecular approaches in male infertility diagnosis Semen analysis remains the cornerstone to accessing male fertility potential despite many drawbacks and fails to predict the male fertility potential with high sensitivity and specificity. The integrity of sperm DNA is crucial for successful fertilization, embryo growth, and the precise transmission of genetic information to progeny. Increasing research suggests that higher sperm DNA fragmentation (SDF) may correlate with clinical varicocele, unexplained infertility, recurrent pregnancy loss, and offspring health. Currently, several tests are available to assess sperm DNA fragmentation in clinical settings. The degree of sperm DNA damage can be measured using the sperm DNA fragmentation index (DFI), which provides more insight into the quality of sperm. Recently, several laboratories have integrated SDF testing into routine semen analysis for the assessment of male infertility. Nonetheless, several aspects of SDF remain unresolved.
This presentation will provide an introduction to existing SDF assays, including recent innovative tests for double-strand breaks (DSBs) in human ejaculated sperm, as well as a discussion on the clinical indications for SDF testing based on recent scientific findings.
TICC - 1F 101D
|
Oncology & Transplantation
TICC - 3F South Lounge
|
||||||
|
15:30
16:00
|
||||||||||